: vimarsana.com

New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on... | May 25, 2023

Related Keywords

United States , Canada , Paris , France General , France , Fabreguettes Leib , Shahram Attarian , Schwartz , University Hospital La Timone , Rare Diseases Network , Neuromuscular Diseases Reference Centers , Open Label Phase , Overall Neuropathy Limitation Scale , Charcot Marie Tooth Disease Type , Overall Neuropathy Limitations Scale , Neuromuscular Diseases , Diseases Network , Lead Investigator , First Double Blind Phase , Open Label Extension , Total Trial , High Dose , Low Dose , Label Extension , Meter Walk Test , Quantified Muscular Testing , Patient Global Impression , Charcot Marie Tooth Neuropathy Score , Euronext Growth , Presse Financi , Pharnext Sa Stock Exchange , News , Information , Press Release , Few , Data , Rom , The , Ngoing , Hase , Wii , Extension , Study , F , Fire , Consistent , Ith , Wood , Safety , Profile , End , Treatment , Effect , Xt3003 , Easured Alpha Fr001400gun7 ,